



EUROPE

The importance of generic medicines to ensuring access to health care and headroom for innovation

Pharmaceuticals and technology programme ,
WHO/EURO

EGA conference, Krakow, Poland, October 5, 2000

Pharmaceuticals and
Technology

WHO/EURO policy framework Health 21


- **Goal : Health for all**
- **Protect health, reduce disease incidence**
- **Human right, equity, solidarity,
participation and accountability**
- **Multi-sectoral action, outcome-oriented,
integrated care, participation**

WHO/EURO roles

- 1. Region's "health conscience"**
- 2. Information centre for health and health development**
- 3. HFA policy promotion and its updating**
- 4. Provision of evidence-based tools to turn policies into action**
- 5. Catalyst for action**
 - Technical cooperation with Member States**
 - Leadership to combat major regional public health threats**
 - Promoting action through networking across Europe**
 - Facilitating emergency preparedness and response**




Trends in life expectancy at birth in Europe



Source: data from the WHO Regional Office for Europe




Infant mortality rate in Europe, around 1995



Source: data from the WHO Regional Office for Europe




Total health expenditure as a percentage of GDP in Europe, 1995 or latest available year



Source: data from the WHO Regional Office for Europe




Drug expenditures US\$ (OECD 1999)





% Rise in drug expenditures 1999 (Scrip, national sources)





Expenditures on medicines in Europe



<i>Expenditure per capita</i>	<i>Western Europe</i>	<i>Eastern Europe</i>	<i>Newly Independent States</i>	<i>Population</i>
> \$300	AUT, BEL, FRA, GER, ICE, SWI			164 mln
\$200 - \$300	DEN, FIN, ITA, LUX, NET, NOR, POR, SWE, GBR			163 mln
\$100 - \$200	GRE, IRE, SPA	CZR, HUN, SLO		76 mln
\$20 - \$100		CRO, EST, LAT, LIT, MAC, POL, SVK	RUS	206 mln
\$10 - \$20		ROM	ARM, BLR, GEO, KAZ, UKR	109 mln
< \$10		ALB	AZE, KGZ, MOL, TJK, TKM, UZB	54 mln

Economic impact

In poor countries drugs are largest household and second largest public expenditure for health

Pharmaceutical spending, as % of total health spending

